Keyt Bruce's Form 4 filing
IGM Biosciences, Inc. (IGMS) · filed Sep 3, 2021
- Accession no.
- 0001209191-21-054913
- Filed
- Sep 3, 2021
- Trade date
- Sep 1-3, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $87.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Keyt BruceCIK 0001787362 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | Common Stock | MOption exerciseAcquired | +2,500 | $0.93 | +$2,325 | 5,557 | Direct | |
| Sep 1, 2021 | Common Stock | FTax withholdingDisposed | −1,256 | $71.79 | −$90,168.24 | 4,301 | Direct | |
| Sep 3, 2021 | Common Stock | SSaleDisposed | −1,244 | $70.69F3 | −$87,938.36 | 3,057 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | Common Stock | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 5,264 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $70.02 to $71.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.